ClinicalTrials.gg
RecruitingNCT07193277Updated Sep 25, 2025

Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy

A Phase 4 interventional study of Butylphthalide and Placebo in Focal Epilepsy and Cognitive Impairment, sponsored by First Affiliated Hospital of Wenzhou Medical University. Recruiting at 1 site in China. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by First Affiliated Hospital of Wenzhou Medical University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsies, Partial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Epilepsies, Partial · China.

Started
2025
the only one that year
Phase 4
2 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
First Affiliated Hospital of Wenzhou Medical University

Among the 10 studies in Epilepsies, Partial with a site in China, this one is the only one that started in 2025, is one of 2 in phase 4, and was the 7th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

6 of the 10 studies in Epilepsies, Partial with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsies, Partial with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of butylphthalide soft capsules for treating cognitive impairment in elderly patients with focal epilepsy.

Study Population: 220 elderly patients (60-85 years) with focal epilepsy and mild to moderate cognitive impairment (Montreal Cognitive Assessment score 18-25).

Intervention: Participants will be randomly assigned 1:1 to receive either butylphthalide soft capsules (0.2g three times daily) or matching placebo for 48 weeks, while continuing their stable anti-seizure medication regimen.

Primary Outcome: Change in Montreal Cognitive Assessment (MoCA) total score from baseline to 48 weeks.

Secondary Outcomes: Changes in neuropsychological tests (Trail Making Test, Digit Span, Rey Auditory Verbal Learning Test), seizure control measures, functional status (Activities of Daily Living, Quality of Life in Epilepsy), and exploratory neurobiological markers.

This study addresses an important unmet medical need, as current epilepsy treatments focus primarily on seizure control but lack effective interventions for epilepsy-associated cognitive impairment. Butylphthalide, a neuroprotective agent approved for acute ischemic stroke in China, has shown promise in other cognitive disorders and may benefit this patient population through its multiple neuroprotective mechanisms.

Read the detailed description

Background and Rationale:

Epilepsy affects approximately 9 million people in China, with focal epilepsy comprising 60-70% of adult cases. Cognitive impairment occurs in 40-60% of elderly patients with focal epilepsy, significantly impacting quality of life and daily functioning. Current anti-seizure medications effectively control seizures in \~70% of patients but provide limited benefit for cognitive symptoms, and some may even worsen cognitive function.

Butylphthalide (DL-3-n-butylphthalide) is a multi-target neuroprotective compound originally derived from celery seeds, approved in China for acute ischemic stroke treatment. Its mechanisms include improving cerebral microcirculation, protecting mitochondrial function, reducing oxidative stress, anti-inflammatory effects, and anti-apoptotic properties. Previous studies have demonstrated efficacy in vascular cognitive impairment and mild cognitive impairment, but its effects in epilepsy-associated cognitive dysfunction remain unexplored.

Study Design:

This investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial will enroll 220 participants across 5 centers in China. The study represents off-label use of butylphthalide for cognitive impairment comorbid with epilepsy.

Participants will undergo comprehensive cognitive assessment including MoCA, Trail Making Tests A/B, Digit Span (forward/backward), Rey Auditory Verbal Learning Test, Activities of Daily Living scale, and Quality of Life in Epilepsy inventory. Exploratory endpoints include functional near-infrared spectroscopy, electroencephalography parameters, and serum biomarkers (BDNF, NGF, NSE, S100β, inflammatory markers).

The 48-week treatment period reflects the chronic nature of cognitive impairment and allows adequate time to detect clinically meaningful changes. Safety monitoring includes regular laboratory assessments, vital signs, and adverse event reporting. A 24-hour emergency contact system ensures participant safety.

Statistical Considerations:

Sample size calculation is based on a minimal clinically important difference of 2.5 points on the MoCA scale, with 80% power and 20% dropout rate. Primary analysis uses ANCOVA comparing 48-week MoCA change scores between groups, adjusting for baseline values and study center. Mixed-effects models will analyze repeated measures for secondary endpoints.

This study may provide evidence for a novel therapeutic approach to epilepsy-associated cognitive impairment, potentially expanding treatment options for this underserved patient population.

03

Conditions studied

  • Focal Epilepsy
  • Cognitive Impairment

Keywords

  • Butylphthalide
  • Focal Epilepsy
  • Cognitive Impairment
  • Elderly
  • MoCA
  • Neuroprotection
  • Randomized Controlled Trial
  • Double-blind
  • Placebo-controlled
  • Multicenter
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 60-85 years (inclusive)
  • Diagnosed with focal epilepsy according to ILAE 2025 latest classification standards, with disease duration ≥2 years
  • Currently receiving stable anti-seizure medication (ASM) treatment for ≥3 months, with good seizure control (monthly seizure frequency ≤4 times in the past 3 months)
  • Cognitive impairment: (MoCA) score 18-25 points (inclusive)
  • Basic Chinese language comprehension and expression ability, able to cooperate with neuropsychological testing
  • Voluntary participation and signed

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with various types of dementia (including Alzheimer's disease, vascular dementia, etc.)
  • Clear history of stroke with corresponding lesions on neuroimaging, or severe white matter lesions on brain MRI
  • Other neurological diseases that may cause cognitive impairment (traumatic brain injury, encephalitis, hydrocephalus, etc.)
  • Systemic diseases that may cause cognitive impairment (severe cardiac, hepatic, renal dysfunction, endocrine diseases, etc.)
  • Current severe depression or other psychiatric diseases affecting cognitive assessment
  • History of alcohol dependence, drug abuse, or other substance use affecting cognitive function
  • Allergy to butylphthalide or its
  • Participation in other drug clinical trials within 30 days
  • Other conditions deemed inappropriate for participation by investigators
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Butylphthalide Group

    Participants receive butylphthalide soft capsules 0.2g (two 0.1g capsules) orally three times daily before meals for 48 weeks, while continuing their stable anti-seizure medication regimen.

    Drug: Butylphthalide

  • Placebo comparator
    Placebo Group

    Participants receive matching placebo capsules orally three times daily before meals for 48 weeks, while continuing their stable anti-seizure medication regimen. Placebo capsules are identical in appearance, weight, and odor to butylphthalide capsules.

    Drug: Placebo

Interventions

  • Butylphthalide soft capsules (0.1g per capsule) manufactured by CSPC NBP Pharmaceutical Co., Ltd. Participants take 2 capsules (0.2g total) orally three times daily, 15-30 minutes before meals, for 48 weeks. This represents off-label use for cognitive impairment comorbid with epilepsy, as the drug is currently approved in China only for acute ischemic stroke treatment.

    Also known as: DL-3-n-butylphthalide, NBP

  • DrugPlacebo

    Matching placebo capsules identical in appearance, weight, and odor to butylphthalide soft capsules, manufactured by the same company following GMP standards. Participants take 2 capsules orally three times daily, 15-30 minutes before meals, for 48 weeks. Placebo contains starch and appropriate excipients.

06

What researchers measure

Primary outcomes

  1. Change in Montreal Cognitive Assessment (MoCA) Total Score from Baseline to 48 Weeks

    The Montreal Cognitive Assessment (MoCA) is a validated cognitive screening tool that evaluates multiple cognitive domains including visuospatial/executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30 points, with higher scores indicating better cognitive function. The primary outcome is the change in MoCA total score from baseline to 48 weeks, calculated as: (MoCA score at 48 weeks) - (MoCA score at baseline). A positive change indicates cognitive improvement, while a negative change indicates cognitive decline.

    Time frame: Baseline and 48 weeks

Secondary outcomes

  1. Trail Making Test Part A (TMT-A) Completion Time Changes

    Trail Making Test Part A (TMT-A) assesses visual scanning speed and psychomotor speed. Participants connect numbered circles in ascending order (1-2-3-4-5...-25). Completion time is measured in seconds, with typical ranges from 15-300 seconds depending on age and education. Lower completion times indicate better performance. The outcome is calculated as: (TMT-A time at assessment point) - (TMT-A time at baseline). A negative change indicates improvement.

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  2. Trail Making Test Part B (TMT-B) Completion Time Changes

    Trail Making Test Part B (TMT-B) assesses executive function including cognitive flexibility and attention switching. Participants alternate between numbers and letters (1-A-2-B-3-C...). Completion time is measured in seconds, with typical ranges from 30-600 seconds depending on age and education. Lower completion times indicate better performance. The outcome is calculated as: (TMT-B time at assessment point) - (TMT-B time at baseline). A negative change indicates improvement.

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  3. Digit Span Forward Test Score Changes

    Digit Span Forward Test assesses attention and short-term memory capacity. Participants repeat number sequences in the same order as presented. Scores range from 0 to 9 points, with higher scores indicating better attention and short-term memory performance. The outcome is calculated as: (Digit Span Forward score at assessment point) - (Digit Span Forward score at baseline). A positive change indicates improvement.

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  4. Digit Span Backward Test Score Changes

    Digit Span Backward Test assesses working memory and mental manipulation abilities. Participants repeat number sequences in reverse order. Scores range from 0 to 8 points, with higher scores indicating better working memory performance. The outcome is calculated as: (Digit Span Backward score at assessment point) - (Digit Span Backward score at baseline). A positive change indicates improvement.

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  5. Rey Auditory Verbal Learning Test (RAVLT) Immediate Recall Score Changes

    Rey Auditory Verbal Learning Test (RAVLT) Immediate Recall assesses verbal learning and immediate memory capacity. Participants recall a 15-word list immediately after the fifth presentation. Scores range from 0 to 15 words correctly recalled, with higher scores indicating better immediate verbal memory performance. The outcome is calculated as: (RAVLT immediate recall score at assessment point) - (RAVLT immediate recall score at baseline). A positive change indicates improvement.

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  6. Rey Auditory Verbal Learning Test (RAVLT) Delayed Recall Score Changes

    Rey Auditory Verbal Learning Test (RAVLT) Delayed Recall assesses long-term verbal memory retention. Participants recall the 15-word list after a 30-minute delay. Scores range from 0 to 15 words correctly recalled, with higher scores indicating better long-term verbal memory performance. The outcome is calculated as: (RAVLT delayed recall score at assessment point) - (RAVLT delayed recall score at baseline). A positive change indicates improvement.

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  7. Average Monthly Seizure Frequency Percentage Change

    Percentage change in average monthly seizure frequency from baseline to each assessment timepoint. Seizure frequency is recorded daily through seizure diary maintained by patients and caregivers, verified during clinical visits. The outcome is calculated as: \[(Average monthly frequency at assessment point) - (Average monthly frequency at baseline)\] / (Average monthly frequency at baseline) × 100%. A negative percentage indicates reduction in seizure frequency (improvement).

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48

  8. Proportion of Participants with ≥50% Reduction in Seizure Frequency

    Percentage of participants achieving at least 50% reduction in average monthly seizure frequency compared to baseline. Response is defined as: (Baseline monthly frequency - Average monthly frequency during weeks 45-48) / Baseline monthly frequency ≥ 50%. Seizure data collected through daily seizure diary and verified by caregivers.

    Time frame: Baseline and 48 weeks

  9. Activities of Daily Living (ADL) Scale Score Changes

    Activities of Daily Living (ADL) Scale is a 14-item assessment tool that evaluates both basic activities of daily living (BADL) including feeding, bathing, grooming, dressing, bowel control, and bladder control, and instrumental activities of daily living (IADL) including using telephone, shopping, food preparation, housekeeping, laundry, transportation, medication responsibility, and financial management. Each item is scored from 1 to 4 points, with total scores ranging from 14 to 56 points. Higher scores indicate greater functional impairment (worse outcome). The outcome is calculated as: (ADL score at assessment point) - (ADL score at baseline). A negative change indicates functional improvement.

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  10. Quality of Life in Epilepsy Inventory-31-Patient weighted (QOLIE-31-P) Score Changes

    Quality of Life in Epilepsy Inventory-31-Patient weighted (QOLIE-31-P) evaluates epilepsy-specific quality of life across 7 domains: seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive functioning, medication effects, and social function. Total scores range from 0 to 100 points, with higher scores indicating better quality of life. The outcome is calculated as: (QOLIE-31-P score at assessment point) - (QOLIE-31-P score at baseline). A positive change indicates improvement.

    Time frame: Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  11. Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)

    Safety and tolerability assessed by incidence of treatment-related adverse events classified and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. All adverse events will be recorded and their relationship to study drug will be assessed by investigators as unrelated, unlikely, possible, probable, or definite.

    Time frame: 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  12. Number of Participants with Serious Adverse Events

    Incidence of serious adverse events (SAEs) defined according to International Conference on Harmonisation (ICH) guidelines as events that result in death, are life-threatening, require inpatient hospitalization or prolongation of existing hospitalization, result in persistent or significant disability/incapacity, are congenital anomaly/birth defect, or are medically important events.

    Time frame: 12 weeks, 24 weeks, 36 weeks, and 48 weeks

  13. Number of Participants with Clinically Significant Hepatic Function Abnormalities

    Incidence of clinically significant hepatic function abnormalities defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 2 times the upper limit of normal (ULN), or total bilirubin greater than 1.5 times ULN as measured by standard laboratory methods.

    Time frame: 24 weeks and 48 weeks

  14. Number of Participants with Clinically Significant Renal Function Abnormalities

    Incidence of clinically significant renal function abnormalities defined as serum creatinine levels greater than 1.5 times the upper limit of normal (ULN) or estimated glomerular filtration rate (eGFR) decrease by ≥25% from baseline as measured by standard laboratory methods.

    Time frame: 24 weeks and 48 weeks

  15. Number of Participants with Clinically Significant Hematological Abnormalities

    Incidence of clinically significant hematological abnormalities including hemoglobin decrease to less than 11 g/dL, white blood cell count less than 3,000/μL or greater than 11,000/μL, or platelet count less than 100,000/μL or greater than 450,000/μL as measured by standard hematology laboratory methods.

    Time frame: 24 weeks and 48 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The data sharing plan is currently under consideration and will be determined in consultation with all participating centers, institutional review boards, and relevant regulatory authorities. Factors being evaluated include compliance with Chinese data protection regulations, patient consent provisions, and journal publication policies. A final decision on individual participant data sharing will be made prior to study completion and updated in this registration record.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 25, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Sep 1, 2028
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07193277
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Collaborators
Taizhou Hospital, Lishui Country People's Hospital, Affiliated Yueqing Hospital of Wenzhou Medical University, The Third Affiliated Hospital of Wenzhou Medical University
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Sep 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Sep 25, 2025

Study contacts

Huiqin Xu, MD
Contact
xuhuiqin@wmu.edu.cn
+86-13858806368
Jiahe Lin, PhD
Contact
linjiahe@wmu.edu.cn
+86-13587572321
Huiqin Xu, MD
principal investigator · Department of Neurology, First Affiliated Hospital of Wenzhou Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Butylphthalide

Start the discussion